cell culture-derived H7N9 influenza vaccine

The cell culture-derived H7N9 influenza vaccine is a pandemic preparedness vaccine designed to protect against the H7N9 subtype of Influenza A virus. This specific vaccine formulation, often identified by the candidate vaccine strain IDCDC-RG56N (derived from A/Anhui/1/2013), is produced using cell culture technology—such as MDCK or Vero cell lines—rather than traditional embryonated chicken eggs. This manufacturing approach allows for more rapid production scaling during a pandemic and avoids the risk of egg-adaptive mutations that can compromise vaccine efficacy. The vaccine is typically an inactivated whole-virus or split-virus preparation administered via intramuscular injection. In Japan, this vaccine is part of the national stockpile and has been evaluated in clinical trials sponsored by the Japan Agency for Medical Research and Development (AMED) to assess its safety and ability to induce protective antibody responses in healthy adults.

Other names

H7N9 influenza vaccineH-7N9 influenza vaccineH 7N9 influenza vaccinecell culture-derived H7N9 vaccine